Kura Oncology, Inc. (KURA)
KURANASDAQ-GSBiotechnology: Pharmaceutical Preparations
$7.91
+0.9800 (+14.14%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $673.43m
- P/E
- –
- EPS, last 4 quarters
- $-3.37
- Dividend yield
- –
- Day range
- –
- 52-week range
- $6.75 to $13.90
- Average volume
- 1.89m
- Previous close
- $6.93
Analysts
10 coveringBuy10 buy, 0 hold, 0 sell
Targets a year out average $26.82, +239.1% from here
Earnings
next estimate $-0.8300Next report Nov 10, 2026
Sep 2025
-49.1%
Dec 2025
-27.8%
Mar 2026
+5.7%
Jun 2026
+13.5%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $20.75m | $17.34m | $18.27m | $20.87m |
| Gross profit | $20.75m | $17.28m | $18.00m | $20.63m |
| Operating income | -$80.00m | -$86.27m | -$78.81m | -$73.01m |
| Net income | -$74.12m | -$81.00m | -$73.33m | -$68.33m |
Last four quarters: revenue $77.22m, margin -384.3%, free cash flow -$117.43m
News
8 latest- Septerna, Inc. (SEPN) Reports Q3 Loss, Lags Revenue EstimatesZacks · 4 hours ago
- Kura Oncology (KURA) Loses 35.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks · 4 days ago
- Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue EstimatesZacks · 5 days ago
- Cytek Biosciences, Inc. (CTKB) Reports Q3 Loss, Tops Revenue EstimatesZacks · 5 days ago
- Qiagen (QGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks · Oct 28, 2026
- Will Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should KnowZacks · Oct 27, 2026
- Kura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin InhibitorMarketBeat · Oct 13, 2026
- Caspian Therapeutics, Kura Oncology Outline Development Path For Diabetes Candidate KO-7246 RTTNews · Oct 13, 2026
The company
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura's pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1 -mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- kuraoncology.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.